Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **collagen injection products** within the **medical aesthetics industry**, highlighting the growth and competitive landscape of this sector [1][5][6]. Company Insights 聚子生物 (Juzi Bio) - **Regulatory Approval**: Juzi Bio has obtained a Class III medical device certificate, enhancing market confidence. New products with increased weight are expected to launch by the end of this year or early next year, albeit at higher prices [1][3]. - **Product Development**: The company plans to introduce multiple collagen-related products, with 1-2 new products expected to be approved in 2026 and another in 2027, creating a comprehensive product matrix to boost market competitiveness [1][4]. - **Sales Performance**: Recent stock price declines are attributed to weaker sales performance during the Double Eleven shopping festival, impacted by competition from international brands and ongoing public sentiment issues [2]. 锦波公司 (Jinbo Company) - **Market Performance**: Jinbo's collagen freeze-dried fiber series has performed well, but profit margins have decreased due to increased competition and falling terminal prices. The introduction of more recombinant collagen products may intensify competition but could also expand market demand [1][8][10]. - **Sales Strategy**: Jinbo is focusing on expanding application ranges and reducing costs to drive market growth. The company is also collaborating with leading institutions for OEM production to enhance product lines [10][22]. Market Dynamics - **Growth Trends**: The collagen injection product line is the third largest in the medical aesthetics market, with a growth rate exceeding 50% since 2022. The micro-aesthetic series is expected to maintain a strong growth trajectory [1][5]. - **Product Pricing and Profitability**: High-margin products like the 10 mg and 12 mg variants have effectively compensated for the slowdown in the 4 mg product line, stabilizing overall growth [1][7]. - **Consumer Trends**: A decline in terminal prices is anticipated to attract younger and lower-tier market customers, expanding the overall market size while reducing the space for non-compliant products [12]. Competitive Landscape - **Market Share**: Recombinant collagen fillers have the potential to replace animal-derived fillers, especially for cost-sensitive consumers. Currently, recombinant collagen occupies 20%-30% of the market share, with significant growth potential remaining [14][15]. - **Unique Advantages**: Recombinant collagen offers lower prices and stable supply compared to animal-derived products, along with compliance and safety advantages, making it a preferred choice in the current regulatory environment [18][19]. Future Outlook - **Market Expansion**: The future growth of recombinant collagen products is promising, with expectations of increased usage as new lower-priced products are introduced and consumer education improves [16]. - **Sales Strategies**: Companies are encouraged to enhance their marketing strategies and strengthen partnerships with medical institutions to improve brand recognition and market acceptance [20][21]. Conclusion - The medical aesthetics industry, particularly in collagen injection products, is poised for significant growth driven by regulatory approvals, innovative product offerings, and strategic market positioning. Companies like Juzi Bio and Jinbo are adapting to competitive pressures while exploring new market opportunities.

巨子生物 20251023 摘要 聚子生物新获批的水光针冻干纤维制剂主要针对面部真皮组织，包括眼 周、眉间和鱼尾纹等部位，预计 2026 年开始贡献利润，单品成长空间 预期为 10 亿人民币左右，有望实现大几千万到一个亿的利润释放。 国内已获批的重组胶原蛋白三类医疗器械主要由锦波生物掌握，其拥有 三个证件，而聚子生物刚刚获得一个证件。其他公司如创建和拉方也在 申请中。 重组胶原蛋白与动物源胶原蛋白相比，具有价格优势、致敏风险较低且 不受宗教信仰限制等优势，市场前景广阔，预计到 2025 年医美市场应 用规模将达到 100 亿人民币。 聚子生物目前有四款产品正在申请阶段，包括两款水光针、一款针对颈 纹的凝胶产品（已进入绿色通道）以及一款用于鼻沟纹和法令纹的交联 重组胶原蛋白凝胶。 聚子生物新获批产品预计将带来约 5 亿元净利润增量，参考锦波生物类 似产品的发展情况，其销售规模可达 15 亿人民币以上。 Q&A 聚子生物的三类医疗器械获证情况如何？ 聚子生物在 2022 年上市时就已经报批了三类医疗器械的申请，经过三年的审 核，终于在 2025 年 10 月 21 日获得了首个三类医疗器械证件。这款产品是水 光针 ...

截至10月22日，巨子生物(02367)今年10月份股价下跌了31.65%。拉长时间线来看，自今年5月20日盘中触及阶段性高点85.14港元以来，巨子生物股价累计最 高跌幅则达到55.18%。也就是说，其股价历经5个月走出了一波"腰斩"行情，而直到10月23日才看到止跌迹象。 了解到，10月23日，巨子生物旗下重组I型α1亚型胶原蛋白冻干纤维获NMPA批准，拿到了III类医疗器械注册证。 受此利好消息影响，10月23日早盘，巨子生物股价冲高，开盘半个小时内股价最高达到43.92港元，涨幅达到13.72%。一根大阳线也结束了巨子生物近期14 连阴的萧条走势。不过早盘冲高后，巨子生物股价并未继续保持拉升态势，而是出现了明显回落，最终收涨6.68%。其冲高回落后能否在后续顺利实现股价 反弹无疑成为投资者关注的焦点。 "腰斩"行情的背后 其实从整体来看，巨子生物的股价在今年是经历一次较大的剧烈波动。 首先从今年年初至5月中旬，公司受去年业绩表现强劲利好影响，股价表现强劲。区间阶段涨幅一度达到70%，并在5月20日创下85.15港元的阶段性高点， 市值突破900亿港元。 此轮行情中，受益于行业内重组胶原蛋白概念推动以及 ...

截至10月22日，巨子生物(02367)今年10月份股价下跌了31.65%。拉长时间线来看，自今年5月20日盘中触及阶段性高点85.14港元以来，巨子生物股价累计最 高跌幅则达到55.18%。也就是说，其股价历经5个月走出了一波"腰斩"行情，而直到10月23日才看到止跌迹象。 智通财经APP了解到，10月23日，巨子生物旗下重组I型α1亚型胶原蛋白冻干纤维获NMPA批准，拿到了III类医疗器械注册证。 受此利好消息影响，10月23日早盘，巨子生物股价冲高，开盘半个小时内股价最高达到43.92港元，涨幅达到13.72%。一根大阳线也结束了巨子生物近期14 连阴的萧条走势。不过早盘冲高后，巨子生物股价并未继续保持拉升态势，而是出现了明显回落，最终收涨6.68%。其冲高回落后能否在后续顺利实现股价 反弹无疑成为投资者关注的焦点。 但从5月下旬开始，公司股价开始急转直下，特别是在"重组胶原测不到"风波爆发后，股价连续多日大幅下跌。例如在5月26日至28日的三个交易日内，股价 便累计下跌约10%。而在后续核心品种"618"表现不及预期以及公司医美注射剂产品审批进度低于预期等因素影响下，巨子生物股价开始持续下跌。 此时市 ...

Core Viewpoint - The company, Giant Bio (2367.HK), experienced a significant intraday stock increase of 13.72%, reaching HKD 43.92, following the announcement of receiving a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen freeze-dried fiber product [1] Group 1: Product Approval - The company’s wholly-owned subsidiary, Shaanxi Giant Bio Technology Co., Ltd., received the medical device registration certificate for its recombinant collagen product [1] - This product is designed for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - It is noted as the first recombinant type I natural sequence collagen injectable product approved in China, showcasing the company's core competencies in technology research and development [1] Group 2: Market Opportunities - The approval of this product enriches the company's product portfolio and presents new opportunities for business development in the skin rejuvenation market [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product marks a significant milestone for the company, enhancing its competitive edge in the skin rejuvenation market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate from the National Medical Products Administration of China for the recombinant type I α1 collagen product [1] - This product is the first recombinant natural sequence collagen injectable approved in China, indicating a breakthrough in the company's product offerings [1] Group 2: Market Opportunities - The approval of this product will enrich the company's product categories and provide new opportunities for business development in the skin rejuvenation market [1] - The company plans to gradually launch and promote this product in accordance with its business strategy, leveraging existing products, brands, and channels to enhance consumer experience [1] Group 3: Competitive Position - The approval reflects the company's core competencies in technology research and development as well as industrialization [1] - The company aims to solidify its leading position in the health and beauty sector through this new product offering [1]

Core Viewpoint - The company has received a medical device registration certificate for its recombinant type I α1 collagen freeze-dried fiber product, marking a significant advancement in its product offerings and potential market opportunities in the skin rejuvenation sector [1] Group 1: Product Approval - The product is the first recombinant type I natural sequence collagen injectable approved in China, showcasing the company's technological research and development capabilities [1] - The approval was granted through a joint review of device and drug assessments, highlighting the regulatory efficiency [1] Group 2: Market Opportunities - The new product will enhance the company's product portfolio and provide new opportunities for business development in the skin rejuvenation market [1] - The company plans to gradually launch and promote the product in accordance with its business strategy, aiming to offer a diverse experience to consumers [1] Group 3: Competitive Position - The approval reinforces the company's leading position in the health and beauty sector, allowing it to strengthen its existing products, brands, and channels [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its competitive edge in the skin rejuvenation market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the recombinant type I α1 collagen freeze-dried fiber product [1] - This product is the first recombinant type I natural sequence collagen injectable product approved in China, indicating a breakthrough in the industry [1] Group 2: Market Opportunities - The approval reflects the company's core competencies in technology research and development, as well as industrialization [1] - The new product will diversify the company's product offerings and create new opportunities for business development in the skin rejuvenation market [1] Group 3: Future Plans - The company plans to gradually launch and promote the product according to its business strategy [1] - There will be a focus on collaboration with existing products, brands, and channels to provide consumers with a more diverse experience [1] - The company aims to strengthen its leading position in the health and beauty sector [1]

Core Viewpoint - Juzi Biotechnology (02367.HK) is experiencing significant stock price volatility due to poor sales performance in live streaming, leading to a decline in market confidence and a substantial drop in stock value [1][2] Group 1: Shareholding and Stock Performance - Juzi Holding, the controlling shareholder, purchased 500,000 shares for approximately HKD 19.3 million, increasing its total holdings to 5.85 billion shares, representing 54.61% of the company's issued shares [1] - The company's stock price recently fell from a high of HKD 87.1 per share on May 20 to a low of HKD 56.2 per share by June 9, resulting in a market value loss exceeding HKD 30 billion [1] - The latest stock price is HKD 38.62, with a market capitalization of HKD 41.36 billion [1] Group 2: Financial Performance - Juzi Biotechnology reported a revenue of HKD 3.113 billion for the first half of 2025, a year-on-year increase of 22.5%, and a net profit of HKD 1.182 billion, up 20.6% [2] - The projected revenue for 2024 is HKD 5.538 billion, reflecting a 57.2% year-on-year growth, with a net profit forecast of HKD 2.061 billion, a 42.4% increase [2] - The company has significantly increased its sales and distribution expenses, with a projected expenditure of HKD 2.008 billion in 2024, up 72.51% from HKD 1.164 billion in 2023 [2] Group 3: Market Position and Challenges - Juzi Biotechnology is a leading player in the restructured collagen market, with its brand Kefu Mei achieving rapid growth and becoming a top domestic brand [2] - The company has faced challenges due to ongoing disputes regarding the authenticity of collagen content, which has affected consumer confidence and market perception [1]

Core Viewpoint - The article discusses the competitive landscape in the functional skincare market, focusing on the rivalry between two prominent female entrepreneurs, Fan Daidi from Xi'an and Yang Xia from Shanxi, as they pivot their companies towards the C-end beauty segment, particularly in the context of the recent Double 11 shopping festival [1][12]. Group 1: Market Dynamics - The Double 11 shopping festival has seen a new brand "Tongpin" rapidly rise in popularity, achieving significant sales growth, with its GMV ranking second in Li Jiaqi's live broadcast [1][5]. - Despite the success of Tongpin, the stock price of Juzhi Biological has been declining, hitting a new low of 40.40 HKD per share, with a total market value of 43.3 billion HKD [2]. - Juzhi Biological's stock has faced continuous declines, while Jinbo Biological's stock also fell, indicating a broader trend of market challenges for both companies [2]. Group 2: Brand Development - Tongpin, established in March 2024, focuses on technology-driven skincare solutions and has launched a limited range of products, including five core items [4]. - The brand's rapid sales growth is attributed to its strategic partnerships with top influencers, particularly in live streaming channels [5]. - During the Double 11 event, Tongpin achieved over 20 million RMB in sales, ranking first among new brands on Tmall [5]. Group 3: Corporate Relationships - Tongpin is closely linked to Jinbo Biological, which provides technical support and has several patented ingredients used in Tongpin's products [7]. - Jinbo Biological's founder, Yang Xia, has actively promoted Tongpin, indicating a strategic shift from B-end medical devices to C-end skincare [1][7]. - Jinbo Biological has recently attracted investment from Zhong Shanshan, founder of Nongfu Spring, further solidifying its market position [12]. Group 4: Industry Implications - The competition between Juzhi Biological and Jinbo Biological reflects a broader trend of blurring lines between pharmaceutical and beauty companies in China's functional skincare market [13]. - The outcome of this rivalry will significantly influence the next industry cycle and determine the leading players in the market [13].